Xin Lang Cai Jing·2025-12-29 06:31Group 1 - The core business of the company is focused on the research, production, and sales of implantable orthopedic medical devices, including joint prostheses and spinal implants [2] - As of September 30, 2025, the company achieved a revenue of 756 million yuan, representing a year-on-year growth of 48.75%, and a net profit attributable to shareholders of 192 million yuan, with a significant increase of 213.21% year-on-year [2] - The company has distributed a total of 359 million yuan in dividends since its A-share listing, with 309 million yuan distributed over the past three years [3] Group 2 - On December 26, the company's stock price fell by 1.82%, with a trading volume of 20.04 million yuan [1] - The financing buy-in amount on December 26 was 2.40 million yuan, while the financing repayment was 2.60 million yuan, resulting in a net financing buy of -0.20 million yuan [1] - The total balance of margin trading for the company as of December 26 was 34.15 million yuan, with the financing balance accounting for 0.50% of the circulating market value, indicating a relatively high level compared to the past year [1]